Previous 10 | Next 10 |
Gainers: Clearside Biomedical (CLSD) +30%, Eloxx Pharmaceuticals (ELOX) +15%, Fusion Pharmaceuticals (FUSN) +14%, Precipio (PRPO) +14%, Ocugen (OCGN) +11%.Losers: PDS Biotechnology (PDSB) -27%, Sage Therapeutics (SAGE) -16%, Neu...
Document Security Systems DSS -41% after secures $43.5M capital via equity raise.PDS Biotechnology PDSB -16% on proposing stock offering.Sage Therapeutics SAGE -12% after disappointing zuranolone secondary data in depression study.Vascular Biogenics VBLT -12...
JuSun/iStock via Getty Images NeuroBo Pharmaceuticals ([[NRBO]] +31.8%) is on course to witness its biggest one-day gain in more than a year today. Last week, the company announced an upcoming Special Meeting scheduled to seek stockholder approval for the issuance of common stock. The of...
NeuroBo Pharmaceuticals (NRBO): Q1 GAAP EPS of -$0.15 beats by $0.01.Cash and Cash Equivalents were $13MPress Release For further details see: NeuroBo Pharmaceuticals EPS beats by $0.01
NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results PR Newswire BOSTON , May 17, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal di...
NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded at a new 52-week low today of $3.33. Approximately 1.1 million shares have changed hands today, as compared to an average 30-day volume of 213,000 shares. NeuroBo Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is en...
Shares of NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded today at $3.20, breaking its 52-week low. So far today approximately 1.1 million shares have been exchanged, as compared to an average 30-day volume of 213,000 shares. Potential upside of 65.6% exists for NeuroBo Pharmaceuticals...
Gainers: Purple Biotech (PPBT) +9%, NeuroBo Pharmaceuticals (NRBO) +7%, Obalon Therapeutics (OBLN) +7%, Dare Bioscience (DARE) +4%, Hoth Therapeutics (HOTH) +2%.Losers: Syndax Pharmaceuticals (SNDX) -28%, Zai Lab (ZLAB) -13%, KalVist...
NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded at a new 52-week low today of $3.17. So far today approximately 1.1 million shares have been exchanged, as compared to an average 30-day volume of 213,000 shares. NeuroBo Pharmaceuticals Inc. share prices have moved between a 52-week high...
NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update Acquisition of ANA Therapeutics provides late-stage COVID-19 clinical development program with numerous key inflection points in 2021 PR Newswire BOSTON , A...
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Inc. Website:
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 PR Newswire CAMBRIDGE, Mass. , July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transfo...
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...